Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02039986 · ClinicalTrials.gov registry record
Ivacaftor (Kalydeco) and Insulin in Cystic Fibrosis (CF)
A clinical trial, sponsored by Children's Hospital of Philadelphia.
- Completed
- Registry status
- 13
- Enrollment target
NCT02039986 is a clinical trial that has completed, run by Children's Hospital of Philadelphia. The registered enrollment target is 13 participants.
The verdict
NCT02039986 has completed, sponsored by Children's Hospital of Philadelphia.
- COMPLETED
- Registry status
- 13 participants
- Enrollment target
Study Summary
This study is aimed at better understanding the impact of ivacaftor upon insulin and incretin secretion and glucose tolerance in patients with Cystic Fibrosis with a glycine (G551D) mutation. Investigators hypothesize that treatment with ivacaftor improves insulin secretion in individuals with CF.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2014-01-06 |
| Est. Completion | 2016-10-11 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02039986
The ClinicalTrials.gov registry entry for NCT02039986 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Hospital of Philadelphia, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT02039986 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02039986 about?
NCT02039986 is a clinical study titled "Ivacaftor (Kalydeco) and Insulin in Cystic Fibrosis (CF)". This study is aimed at better understanding the impact of ivacaftor upon insulin and incretin secretion and glucose tolerance in patients with Cystic Fibrosis with a glycine (G551D) mutation. Investigators hypothesize that treatment with ivacaftor improves insulin secretion in individuals with CF.
What is the current status of trial NCT02039986?
This trial is currently completed. The enrollment target is 13 participants. The study started on 2014-01-06. Estimated completion is 2016-10-11.
Who is sponsoring clinical trial NCT02039986?
This trial is sponsored by Children's Hospital of Philadelphia, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.